Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 729 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pred-forte Clear all
Not listed Phase 2 Interventional

Caudal Corticosteroid vs. Dextrose Injection for Lumbosacral Radicular Pain.

NCT02116075
View directory record Official record
Conditions
no Conditions
Interventions
Epidural Prolotherapy, Epidural Steroid
Procedure
Lead sponsor
Naveed Natanzi
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 24, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

NCT02887976
View directory record Official record
Conditions
Prostate Cancer
Interventions
SoluMatrix™ Abiraterone Acetate, Methylprednisolone
Drug
Lead sponsor
GU Research Network, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Wichita, Kansas • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 24, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

NCT02282514
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 24, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 24, 2026, 2:24 PM EDT
Recruiting Phase 2 Interventional

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

NCT06780202
View directory record Official record
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 24, 2026, 2:24 PM EDT
Not listed No phase listed Observational

PREdicting Atrial Fibrillation or Flutter

NCT01851902
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00443430
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02596971
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions
Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Not applicable Interventional Results available

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

NCT02954198
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus, Prednisone, Mycophenolate mofetil, Everolimus
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 24, 2026, 2:24 PM EDT
Recruiting Phase 4 Interventional

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

NCT07217405
View directory record Official record
Conditions
Osteoarthritis Hand, Osteoarthritis Wrist
Interventions
Corticosteroid injection (CSI), Low-dose radiotherapy (LDRT)
Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Medial Branch Blocks vs. Intra-articular Injections: Randomized, Controlled Study

NCT02002429
View directory record Official record
Conditions
Lumbar Facet Joint Pain, Low Back Pain
Interventions
Intra-articular injection, Medial branch block, Saline injection
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 24, 2026, 2:24 PM EDT
Not listed Phase 4 Interventional Results available

Descemet Endothelial Thickness Comparison Trial

NCT02373137
View directory record Official record
Conditions
Keratoplasty, Grafting, Corneal, Transplantation, Corneal, Transplantation, Cornea, Keratoplasty, Lamellar
Interventions
DSAEK, DMEK, Endoserter, Prednisolone, Ofloxacin, Tropicamide, Phenylephrine, Jones Tube
Procedure · Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
View directory record Official record
Conditions
DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
Biological · Other · Procedure + 1 more
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

NCT05587673
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Intraductal Meibomian Gland Probing Trial

NCT02256969
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Blephamide, GenTeal PM Night-Time, Meibomian Gland Probing, Sham Meibomian Gland Probing
Drug · Procedure
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
BRII-296, Depo Medrol
Drug
Lead sponsor
Brii Biosciences Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 24, 2026, 2:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
24
States / cities
Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Not applicable Interventional Results available

Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery

NCT02219087
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Liposomal bupivacaine, Standard of Care
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 24, 2026, 2:24 PM EDT
Withdrawn Phase 2 Interventional

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

NCT01028313
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease
Interventions
LBH589, Methylprednisolone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 24, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

NCT04411667
View directory record Official record
Conditions
Sars-CoV2
Interventions
Octagam
Drug
Lead sponsor
George Sakoulas, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 24, 2026, 2:24 PM EDT